Logos Global Management as of Sept. 30, 2020
Portfolio Holdings for Logos Global Management
Logos Global Management holds 46 positions in its portfolio as reported in the September 2020 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Alx Oncology Hldgs (ALXO) | 15.6 | $118M | 3.1M | 37.74 | |
| Keros Therapeutics (KROS) | 8.1 | $62M | 1.6M | 38.57 | |
| Nkarta (NKTX) | 8.1 | $62M | 2.0M | 30.06 | |
| Forma Therapeutics Hldgs SHS | 7.7 | $59M | 1.2M | 49.84 | |
| Global Blood Therapeutics In | 6.2 | $47M | 850k | 55.14 | |
| Tg Therapeutics (TGTX) | 6.2 | $47M | 1.8M | 26.76 | |
| Sarepta Therapeutics (SRPT) | 5.1 | $39M | 275k | 140.43 | |
| Repare Therapeutics Ord (RPTX) | 4.0 | $30M | 977k | 30.77 | |
| Bioxcel Therapeutics (BTAI) | 3.1 | $24M | 550k | 43.36 | |
| Avidity Biosciences Ord (RNA) | 2.7 | $20M | 722k | 28.15 | |
| Celldex Therapeutics Com New (CLDX) | 2.3 | $18M | 1.2M | 14.83 | |
| Compass Pathways Sponsored Ads (CMPS) | 2.3 | $18M | 500k | 34.90 | |
| Cytokinetics Com New (CYTK) | 2.1 | $16M | 750k | 21.65 | |
| Dyne Therapeutics (DYN) | 2.1 | $16M | 800k | 20.19 | |
| Sage Therapeutics (SAGE) | 2.0 | $15M | 250k | 61.12 | |
| Calliditas Therapeutics Ab Sponsered Ads | 1.7 | $13M | 550k | 24.00 | |
| Bristol-myers Squibb Right 99/99/9999 | 1.6 | $12M | 5.5M | 2.25 | |
| Athira Pharma (ATHA) | 1.5 | $11M | 610k | 18.46 | |
| Kymera Therapeutics (KYMR) | 1.3 | $9.7M | 301k | 32.31 | |
| Nurix Therapeutics (NRIX) | 1.3 | $9.6M | 275k | 34.91 | |
| Harmony Biosciences Hldgs In (HRMY) | 1.2 | $9.3M | 275k | 33.90 | |
| Iteos Therapeutics (ITOS) | 1.0 | $7.4M | 300k | 24.67 | |
| Therapeutics Acquisition Cor Com Cl A | 0.9 | $7.2M | 500k | 14.38 | |
| Akouos | 0.9 | $7.1M | 310k | 22.87 | |
| Unum Therapeutics Ord | 0.8 | $6.3M | 2.7M | 2.34 | |
| Inhibrx | 0.7 | $5.6M | 312k | 18.00 | |
| Lifesci Acquisition Corp Unit 03/31/2025 | 0.7 | $5.4M | 400k | 13.60 | |
| Pmv Pharmaceuticals (PMVP) | 0.7 | $5.3M | 150k | 35.50 | |
| Pandion Therapeutics | 0.7 | $5.2M | 450k | 11.46 | |
| Larimar Therapeutics (LRMR) | 0.7 | $5.0M | 330k | 15.17 | |
| Outset Med (OM) | 0.7 | $5.0M | 100k | 50.00 | |
| Annexon (ANNX) | 0.6 | $4.8M | 160k | 30.23 | |
| Passage Bio (PASG) | 0.6 | $4.5M | 344k | 13.11 | |
| Relay Therapeutics (RLAY) | 0.6 | $4.3M | 100k | 42.59 | |
| Kalvista Pharmaceuticals (KALV) | 0.5 | $3.8M | 300k | 12.59 | |
| Black Diamond Therapeutics (BDTX) | 0.5 | $3.7M | 124k | 30.23 | |
| Inari Medical Ord (NARI) | 0.5 | $3.5M | 50k | 69.02 | |
| Health Sciences Acq Corp 2 Ord Shs | 0.4 | $3.3M | 300k | 11.00 | |
| Pliant Therapeutics (PLRX) | 0.4 | $3.1M | 137k | 22.65 | |
| Panacea Acquisition Corp Unit 99/99/9999 | 0.3 | $2.4M | 200k | 12.00 | |
| Acutus Medical (AFIB) | 0.3 | $2.2M | 75k | 29.80 | |
| Chardan Healthcr Acqstn 2 Unit 99/99/9999 | 0.3 | $2.1M | 200k | 10.55 | |
| Bctg Acquisition Corp | 0.3 | $2.1M | 200k | 10.36 | |
| Fs Dev Corp Com Cl A | 0.1 | $1.1M | 100k | 11.20 | |
| Arya Sciences Acquistion Unit 06/09/2027 | 0.1 | $1.1M | 100k | 11.00 | |
| Rapt Therapeutics (RAPT) | 0.1 | $1.0M | 31k | 32.19 |
